Skip to content
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital […]
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
(Image Credit: United) With the planet warming at an increasing clip and having an impact on everything from human health to food and energy
How LanzaTech and Virent are fueling the energy transition – with biotech Read More »
Two Biotechnology Innovation Organization (BIO) members – BioMarin and Twist Bioscience – were recognized at the 2023 Pantheon Awards on Wednesday for innovative achievements
BioMarin, Twist Bioscience win CLS Pantheon Awards Read More »
Cardiovascular disease (CVD) is the leading cause of death worldwide and is responsible for over 900,000 deaths in the U.S. annually—and hypercholesterolemia, or elevated
A promising oral pill for ‘bad cholesterol’ is exciting news for heart patients Read More »
With a growing population, scientists are looking for new, more sustainable ways to meet the global demand for food, fuel, drugs, and other manufactured
How synthetic biology is revolutionizing our lives Read More »
Remarks from Dr. Ted W. Love, Chairman of the Biotechnology Innovation Organization (BIO) and former President and CEO of Global Blood Therapeutics, as prepared
Dr. Ted W. Love: How to reframe the narrative about biotech – and put patients first Read More »
Amgen Inc., an Advocate level sponsor of the 2023 BIO Patient & Health Advocacy Summit, provided their approval to share this previously published article
A bill to incentivize production of low-carbon biofuels by ensuring that the environmental benefits of these fuels are measured accurately when assessing tax credits
Bill seeks accurate measures of how well biofuels cut carbon emissions Read More »
The U.S. Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib) as a treatment for a rare blood cancer, the agency said in an
Rare blood cancer drug wins FDA approval Read More »
Dr. Mary-Ann Etiebet, Associate Vice President, Health Equity, Merck, has more than two decades of experience working across the public and private sectors to
Turning insights into action: building a U.S. health system that delivers for all women Read More »
